🔴 Regeneron Pharmaceuticals is trading 5% down in pre-market — no confirmed catalyst identified

Regeneron Pharmaceuticals is trading 5% down at $755.51 after falling from the September 21 close of $798.17, with no confirmed September 22 company announcement, earnings release, regulatory action, or analyst call directly explaining the pre-market decline.

• A September 21 court ruling favored the company in one investor lawsuit.
• Separate Fianlimab-Libtayo securities litigation remains earlier background rather than a confirmed catalyst.
• Broader markets are mixed, offering limited directional explanation.